MENLO PARK, Calif.--(BUSINESS WIRE)--Recida Therapeutics, Inc. announced today the initiation of a Phase I trial for RC-01, a novel LpxC inhibitor. The trial is being conducted in the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback